Skip to content

Partner with OCRA to Drive Cancer Research and Support

Industry Partnerships

We partner with leading pharmaceutical, biotechnology, and diagnostic companies to support and strengthen OCRA's mission.

Why Partner with OCRA?

As the leading ovarian cancer organization in the world, we recognize that stakeholder collaboration is key to achieving our goal of curing gynecologic cancers and ensuring the development of safe, more effective therapies. We work with our partners to fulfill our shared goals of raising awareness, supporting patients, emphasizing education, and advancing critical research and treatment options.

Partnering with OCRA helps bring your clinical work full circle, supporting patients through every stage of their journeys. By collaborating with us, industry partners gain a better understanding of patient needs, helping ensure developments that address their concerns, while gaining an increased focus on real-world data.

Ways We Collaborate with Industry

We have a number of year-round sponsorship and support opportunities for partners, from patient support and education, to advocacy, to our International Conference, as well as our Gynecologic Cancer Collaborative. OCRA also engages with partners to increase awareness through unbranded communications campaigns and opportunities to elevate the patient voice in therapy development. Please contact us if you wish to learn more about our work and how we can partner to better serve and support the gynecologic cancer community.

At present, OCRA does not engage with partners for paid advertisements on our website or digital/print publications and newsletters. We do have opportunities for brand awareness and advertisements via our International Gynecologic Cancer Conference.

For more information, please contact Jessica Hughson-Andrade at jhughson-andrade@ocrahope.org


Pharmaceutical Partners

Anixa Biosciences
Corcept Therapeutics logo
Mercy Bioanalytics logo
Regeneron Science to Medicine logo
Sutro Biopharma
TCR Therapeutics logo
VBL Logo

Conflict of Interest Statement — Industry Partners

  • Corporate partners including industry do not shape OCRA’s agenda, research, or advocacy.
  • In 2023, industry partners represented 8% of OCRA’s overall revenue.
  • If an industry partner sponsors an OCRA program, grant, or educational materials, it is publicly acknowledged and the supporting company has no editorial or strategic input.
  • Any reference to a specific commercial product or service does not constitute or imply an endorsement by OCRA of the product or service or its producer or provider. The views and opinions expressed in any referenced document or on any referenced website do not necessarily reflect those of OCRA.
Read our conflict of interest policy

Related Topics

Action Alert: Urge Congress to Pass Final Bill on Cancer Research Funding and Early Detection

Action Alert: Urge Congress to Pass Final Bill on Cancer Research Funding and Early Detection

The Congressional Appropriations Committees have released a combined FY2026  Defense/Labor, Health and Human Services bill—and it includes several critical investments and policy provisions that would significantly strengthen the federal response to ovarian and other gynecologic cancers. This bill represents meaningful progress for our community, but it is not final. Congress must act swiftly to advance and … Continued

Read more

OCRA Urges Immediate Passage of Bill Supporting Ovarian Cancer Research, Education, and Early Detection

OCRA Urges Immediate Passage of Bill Supporting Ovarian Cancer Research, Education, and Early Detection

The Ovarian Cancer Research Alliance today praised the release of the FY2026 Labor, Health and Human Services, Education, and Related Agencies appropriations bill by the Congressional Appropriations Committees and urged swift action to advance and enact the legislation. The bill includes critical funding and policy provisions supporting ovarian cancer research, education, and early detection. Add Your Voice … Continued

Read more

Ovarian Cancer Research Alliance Reports Year of Significant Progress Across Research, Advocacy, and Patient Support

Ovarian Cancer Research Alliance Reports Year of Significant Progress Across Research, Advocacy, and Patient Support

Organization launches global initiatives, expands patient programs, strengthens policy leadership, and achieves record engagement in 2025 OCRA is grateful for our community’s generous support, which helped raise over $2.4 million, surpassing our year-end campaign goal and closing out a year of progress.  NEW YORK, NY — [January 13, 2026] — In 2025, Ovarian Cancer Research Alliance (OCRA) delivered … Continued

Read more

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.